UV Suppresses Immunity — That's Not Simply Good or Bad. Here's the Ledger.

UV-induced immune suppression is one of the most well-characterized effects of sun exposure on human biology. It is also one of the most poorly communicated. Public messaging alternates between "UV suppression protects against autoimmunity" (wellness framing) and "UV suppression increases cancer risk" (oncology framing) as if these are competing narratives. They are not — they are both true, and understanding their relative magnitudes across dose and pattern is the actual scientific question.

The claim this post makes: the autoimmune-protective benefit of UV immune suppression predominates at regular moderate UV doses consistent with habitual outdoor activity. The carcinogenic cost predominates at cumulative high-dose exposure and intermittent sunburn patterns. These are not offsettable in the aggregate — they operate through overlapping mechanisms on different outcome timescales — but the dose-pattern distinction is real and should drive population guidance rather than binary avoidance or indulgence messaging.

This post builds the risk-benefit ledger directly.

What UV immune suppression actually is

UV exposure produces two distinct tiers of immune suppression:

Local suppression is specific to the UV-exposed skin and its draining lymph nodes. It involves:

• Langerhans cell depletion from the epidermis (UVB primarily)
• Induction of regulatory T cells (Tregs) in skin-draining lymph nodes
• Elevation of immunosuppressive cytokines: IL-10, TGF-β
• Urocanic acid (trans-to-cis isomerization in stratum corneum) acting as a UV-responsive immunomodulator via 5-HT2A receptors on dendritic cells (El-Ghorr & Norval, J Immunol 1995)
• S1P-mediated T cell retention in skin-draining lymph nodes (see 0012)

Systemic suppression occurs at higher doses and is less well characterized. It involves circulating regulatory T cells, POMC-derived neuropeptides released by UV-activated keratinocytes, and systemic IL-10 elevation. This can suppress immune responses to antigens at sites distant from the exposed skin.

Both tiers are dose-dependent. Both are real.

The autoimmune protection side

The epidemiological evidence for UV as a protective factor in autoimmune diseases is strongest for multiple sclerosis:

• Latitude gradient: MS prevalence increases ~5–10× from equatorial to high-latitude populations, tracking UV exposure more closely than any other candidate (Compston & Coles, Lancet 2008)
• Migration studies: Individuals who migrate from low-to-high latitude before adolescence acquire the higher-latitude MS risk; adults who migrate do not — implicating UV exposure during development as critical (Gale & Martyn, BMJ 1995)
• Mechanistic candidates: Vitamin D (Mendelian randomization supports causality; Mokry et al., Ann Neurol 2015) and S1P-mediated immune trafficking (see 0012) both operate downstream of UV and are consistent with the epidemiological pattern

Evidence also supports UV-protective associations in inflammatory bowel disease, type 1 diabetes, and rheumatoid arthritis — all showing inverse associations with UV exposure in ecological and cohort studies, with less developed mechanistic evidence than for MS.

The cancer risk side

UV-induced immunosuppression is a well-established co-factor in skin carcinogenesis. The mechanism: UV creates characteristic CC→TT pyrimidine dimer mutations in keratinocytes. Normally, these are cleared by immune surveillance (NK cells, CD8+ cytotoxic T cells). UV-induced local immunosuppression — Langerhans cell depletion and Treg induction — impairs this surveillance, allowing UV-mutated cells to accumulate additional mutations.

The quantitative evidence:

• Organ transplant recipients on immunosuppressive drugs have 65–250× higher rates of squamous cell carcinoma — directly demonstrating the anti-cancer role of intact skin immune surveillance (Euvrard et al., NEJM 2003)
• UV exposure is the dominant cause of the three major skin cancers (BCC, SCC, melanoma) — an unambiguous causal relationship
• Melanoma risk is driven predominantly by intermittent high-dose episodes and sunburn history, not simply cumulative dose

The same S1P/lymph-node-trapping mechanism that may protect against autoimmunity by sequestering T cells also reduces T cell surveillance of UV-mutated epidermal cells. This is not two separate mechanisms — it is the same biology producing protective and deleterious outcomes simultaneously, at the same receptor.

The risk-benefit ledger

The reconciliation: dose and pattern

The autoimmune-protective effect appears to operate at UV doses consistent with regular moderate outdoor activity. The skin cancer risk is strongly driven by cumulative dose (SCC) and intermittent high-dose / sunburn episodes (melanoma). Regular moderate sun exposure with avoidance of sunburn may capture the immunomodulatory benefit while minimizing the carcinogenic risk accumulation.

This is the falsifiable claim: if this framing is correct, a population with habitual moderate UV exposure (no sunburn) should show lower autoimmune disease rates and lower melanoma risk than both chronic UV avoiders (who lose the autoimmune benefit) and intermittent high-dose sunners (who accumulate melanoma risk without proportional additional autoimmune benefit). That cross-sectional prediction is testable in existing cohort data with sufficient UV behavioral granularity.

What this means for public health messaging

"Avoid UV" and "get more sun" are both too crude. The evidence supports a more precise framing: regular moderate sun exposure with sunburn prevention. The dose and pattern matter more than the direction.

Community question: Has anyone modeled the joint risk-benefit curve for MS-preventive versus melanoma-risk UV doses in the same population? The cross-over point — at which cancer hazard exceeds autoimmune benefit as a function of skin type, latitude, and age of exposure initiation — is the analysis that should be driving public health UV guidance but, to our knowledge, doesn't yet exist.